Anand Bhatt, MD
Glaucoma Specialist · Santa Ana, CANPI 1831358977
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,300 of the $7,589 with a category attached, or 69.8%. Alcon accounts for 75.3% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2023 at $4,700 and has fallen 95.8% since, to $197 in 2025.
Across 101 payments — averaging $75.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$6K
- AbbVie$389
- Sight Sciences, Inc.$327
- Rxsight Inc$211
- Aerie Pharmaceuticals, Inc.$180
- Regeneron Healthcare Solutions, Inc.$135
- plus $634 from 14 others
Across 7 payments — averaging $3142.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$22K
What the payments were for
- Speaking & faculty fees$5,30070%
- Food & beverage$2,28930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 24 | $5,712 |
| AbbVie(2 entities) | 17 | $389 |
| Sight Sciences, Inc. | 10 | $327 |
| Rxsight Inc | 8 | $211 |
| Aerie Pharmaceuticals, Inc. | 8 | $180 |
| Regeneron Healthcare Solutions, Inc. | 1 | $135 |
| Sun Pharmaceutical Industries Inc. | 5 | $107 |
| NEW World Medical,inc. | 6 | $99 |
| Novartis | 5 | $79 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $62 |
| Eyevance Pharmaceuticals LLC | 3 | $49 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $44 |
| Thea Pharma Inc. | 2 | $39 |
| Shire North American Group Inc | 1 | $25 |
| Glaukos Corporation | 1 | $24 |
| Akorn, Inc. | 1 | $23 |
| Oyster Point Pharma, Inc. | 1 | $22 |
| Kala Pharmaceuticals, Inc. | 1 | $22 |
| Akorn Operating Company LLC | 1 | $21 |
| Carl Zeiss Meditec USA, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEARCARE SYSTEM$143
- EYLEA$135
How this compares
$7,589 in reported general payments places this provider in the 70th percentile of 64 glaucoma specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 212 | $121,209 |
| RestasisCyclosporine | 51 | $63,896 |
| RhopressaNetarsudil Mesylate | 95 | $55,156 |
| RocklatanNetarsudil Mesylat/Latanoprost | 69 | $43,793 |
| XiidraLifitegrast | 29 | $33,433 |
| Cyclosporine | 49 | $25,289 |
| Prednisolone Acetate | 582 | $21,785 |
| Alphagan PBrimonidine Tartrate | 43 | $21,161 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 826 | $20,641 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 53 | $20,160 |
| Latanoprost | 1,565 | $19,716 |
| VyzultaLatanoprostene Bunod | 29 | $18,109 |
| CombiganBrimonidine Tartrate/Timolol | 46 | $17,593 |
| AzoptBrinzolamide | 23 | $13,855 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 46 | $10,574 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P, Combigan | $389 | $223,858352 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $180 | $98,949164 claims |
| AlconSimbrinza, Azopt | $5,712 | $34,01576 claims |
| Thea Pharma Inc.Iyuzeh | $39 | $6,97018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 64 glaucoma specialist providers in California.
Other glaucoma specialist in Santa Ana
- Jason BacharachPetaluma$1.7M
- Billy PanBeverly Hills$250K
- Jacob BrubakerSacramento$229K
- Felise May BarteSanta Clara$121K
- Houman VosoghiWestlake Village$119K
- Robert ChangStanford$105K
- Sophia WangStanford$77K
- Jeffrey GoldbergStanford$57K
- Valentina LozanoCulver City$51K
- Sameh MosaedIrvine$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.